Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
InflaRx NV (IFRX)
NASDAQ:IFRX
Holding IFRX?
Track your performance easily
IFRX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.14 - $2.10
Previous Close$1.53
Volume95.96K
Average Volume (3M)72.89K
Market Cap
$90.09M
Enterprise Value$77.42M
Total Cash (Recent Filing)€12.77M
Total Debt (Recent Filing)€1.12M
Price to Earnings (P/E)―
Beta0.68
Next Earnings
Mar 20, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.86
Shares Outstanding58,883,272
10 Day Avg. Volume65,396
30 Day Avg. Volume72,894
Standard Deviation0.32
R-Squared0.07
Alpha0.00910
Financial Highlights & Ratios
Price to Book (P/B)0.87
Price to Sales (P/S)1281.54
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$6.50Price Target Upside330.46% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
InflaRx News
PremiumPre-Earnings
Is IFRX a Buy, Before Earnings?
PremiumCompany Announcements
InflaRx N.V. Reports Mid-Year Financial Results
PremiumCompany Announcements
InflaRx Announces $75M Share Sales Agreement
PremiumCompany Announcements
InflaRx’s Drug Enters BARDA Phase 2 ARDS Trial
Bulls Say, Bears Say
Bulls Say
Financial PerformanceThe company remains well-capitalized into 2026.
Regulatory AchievementsGohibic received FDA Emergency Use Authorization for the treatment of critically ill COVID-19 patients.
Research And DevelopmentINF904 has the potential to improve upon other oral complement inhibitors, including ChemoCentryx’s Tavneos, an approved treatment for Anca-associated vasculitis.
Bears Say
EarningsInflaRx reported 2Q24 EPS of (€0.24), which is significantly below both the analyst's estimate of (€0.16) and the consensus of (€0.20).
Financial PerformanceThe full-year EPS estimate has been decreased to (€0.89) from (€0.66), reflecting a more pessimistic outlook for the company's financial performance.
RevenueRevenue estimates have been significantly lowered to €0.1M from €0.5M, indicating potential challenges in the company's ability to generate income.
---
Ownership Overview
―
Insiders
0.06% Mutual Funds
0.16% Other Institutional Investors
99.78% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
IFRX FAQ
What was InflaRx NV’s price range in the past 12 months?
InflaRx NV lowest stock price was $1.14 and its highest was $2.10 in the past 12 months.
What is InflaRx NV’s market cap?
Currently, no data Available
When is InflaRx NV’s upcoming earnings report date?
InflaRx NV’s upcoming earnings report date is Mar 20, 2025 which is in 132 days.
How were InflaRx NV’s earnings last quarter?
Currently, no data Available
Is InflaRx NV overvalued?
According to Wall Street analysts InflaRx NV’s price is currently Undervalued.
Does InflaRx NV pay dividends?
InflaRx NV does not currently pay dividends.
What is InflaRx NV’s EPS estimate?
InflaRx NV’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does InflaRx NV have?
InflaRx NV has 58,883,270 shares outstanding.
What happened to InflaRx NV’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of InflaRx NV?
Among the largest hedge funds holding InflaRx NV’s share is Woodline Partners LP. It holds InflaRx NV’s shares valued at 302K.
---
InflaRx Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.50 (330.46% Upside)
$6.50 (330.46% Upside)
Hedge Fund Trend
Increased
By 173.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 3.7%
Last 30 Days ▼ 0.2%
Last 30 Days ▼ 0.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
11.67%
12-Months-Change
Fundamentals
Return on Equity
-45.19%
Trailing 12-Months
Asset Growth
-31.26%
Trailing 12-Months
Company Description
InflaRx NV
InflaRx NV is a clinical-stage biopharmaceutical company, which engages in the discovery and development of inhibitors of the complement activation factor known as C5a. Its products includes IFX-1 and IFX-2. The company was founded by Niels Christoph Riedemann, Renfeng Guo and Nicolas Fulpius in December 2007 and is headquartered in Jena, Germany.
---
IFRX Stock 12 Month Forecast
Average Price Target
$6.50
▲(330.46% Upside)
Technical Analysis
EyePoint Pharmaceuticals
―
Forte Biosciences
―
TG Therapeutics
―
Cyclacel Pharmaceuticals
―
Best Analysts Covering IFRX
1 Year
1 Year Success Rate
12/28 ratings generated profit
1 Year Average Return
+1.90%
reiterated a buy rating last month
Copying Edward White's trades and holding each position for 1 Year would result in 42.86% of your transactions generating a profit, with an average return of +1.90% per trade.
---